CSF1
EmergingCSF1 overexpression drives tenosynovial giant cell tumor, now treatable with two different CSF1 receptor inhibitor drugs.
CSF1 is a signaling protein that, when overproduced due to a gene abnormality, drives a rare joint tumor by recruiting certain immune cells. Two different drugs now exist that block this pathway directly, with the newest approved in 2025.
Colony stimulating factor 1 (CSF1, also called M-CSF) is a cytokine that regulates the production, differentiation, and function of macrophages by signaling through the CSF1 receptor (CSF1R).
CSF1 gene translocation and overexpression drives tenosynovial giant cell tumor (TGCT), a rare, locally aggressive joint tumor, by recruiting CSF1R-expressing macrophages into the tumor mass.
Diagnosis of TGCT is primarily via imaging and tissue biopsy showing characteristic CSF1-driven macrophage infiltration; CSF1 itself is not a standard blood test but underlies the molecular rationale for targeted therapy.
This led to pexidartinib (FDA-approved 2019) and, very recently, vimseltinib (FDA-approved 2025) — a second, more selective CSF1 receptor inhibitor for TGCT patients who aren't good surgical candidates, representing a genuinely active and evolving area of targeted oncology drug development.
A 2025 second-generation CSF1R inhibitor (vimseltinib) reflects an actively evolving targeted therapy area.
- FDA. (2025). Vimseltinib Approval for Tenosynovial Giant Cell Tumor.
- General oncology reference literature on CSF1/CSF1R pathway in TGCT.